Polymer-free Amphilimus™ (Sirolimus + Fatty Acid) eluting stent for lesions in the SFA region.
The absence of polymer minimizes the risk of inflammation/thrombosis, while the proprietary formulation enhances drug absorption.
The proprietary polymer-free Abluminal Reservoir Technology allows a sustained drug release, exclusively towards the vessel wall, up to 3 months, eliminating the renowned drawback associated to the polymers
The Amphilimus™ formulation (Sirolimus + Fatty Acid) enhances drug bioavailability, permeability and maximizes product overall safety and efficacy
Thanks to its haemo and bio- compatibility, the Bio Inducer Surface acts as anti-thrombotic coating and it promotes a fast-healing sealing against heavy metal ions release
The drug efficacy is maximized by the prolonged, controlled and targeted elution to the vessel wall. The endothelialization process is not delayed by the presence of any polymer or drug.
In diabetic cells, as glucose uptake and oxidation are impaired, the uptake of fatty acids is increased in the ATP pathway which also improves the availability of the Sirolimus.
In the very distal arteries, where the blood speed is slow and the platelet interaction with the stent surface is prolonged, the coating contributes to increase device safety.
Peripheral stent
Drug releasing formulation
Device specifications
